

ALLEGATO A

UNIVERSITÀ DEGLI STUDI DI MILANO

Procedura di selezione per la chiamata a professore di II fascia da ricoprire ai sensi dell'art. 18, commi 1 e 4, della Legge n. 240/2010 per il settore concorsuale 06/A2 - Patologia Generale e Patologia Clinica (settore scientifico-disciplinare MED/04 - Patologia Generale) presso il Dipartimento di BIOTECNOLOGIE MEDICHE E MEDICINA TRASLAZIONALE, Codice concorso 5433

CURRICULUM VITAE

Alessandra Mortellaro

INFORMAZIONI PERSONALI

COGNOME	MORTELLARO
NOME	ALESSANDRA ROSA
DATA DI NASCITA	25/04/1971
CITTADINANZA	ITALIANA
LINGUE PARLATE	ITALIANO, INGLESE

TITOLI

TITOLO DI STUDIO

Febbraio 1998: Laurea Quinquennale in Scienze Biologiche conseguita presso l'Università Statale di Milano

TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO

Ottobre 2006: Doctor of Philosophy (PhD) rilasciata da Open University of London (United Kingdom)

ALTRI TITOLI CONSEGUITI

Giugno 2022: Abilitazione Nazionale Professore Prima Fascia e Seconda Fascia in Patologia Generale e Clinica (Settore 06/A2)

Giugno 2022: Abilitazione Nazionale Professore Prima Fascia e Seconda Fascia in Istologia (Settore 05/H2)

POSIZIONI LAVORATIVE

2021-oggi	Group Leader	San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milano
2017-2021	Project Leader	San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milano
2011-2017	Principal Investigator	Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore
2010-2011	Senior Research Scientist	Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore
2008-2010	Research Scientist	Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore
2006-2007	Postdoctoral Fellow	Department of Biotechnology and Bioscience, Università degli Studi di Milano-Bicocca
2001-2005	PhD Student	San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milano

ATTIVITÀ DIDATTICA

INSEGNAMENTI E MODULI

2005-2008	Docente a contratto, Corso di Biologia Integrata (Modulo di Immunologia), Università di Milano-Bicocca
2005-2008	Docente a contratto, Laboratorio di Tecniche Immunologiche (Classi Teoriche e Pratiche), Corso di Biotecnologia
2015-2017	Professore Associato Aggiunto, Seminari, Dipartimento di Microbiologia and Immunologia, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore (11 th in the QS World University Rankings 2022)
2017	Professore Associato Aggiunto, School of Biological Sciences (SBS), Nanyang Technological University (NTU), Singapore (12 th in the QS World University Rankings 2022)

ATTIVITÀ DI DIDATTICA INTEGRATIVA E DI SERVIZIO AGLI STUDENTI

ATTIVITÀ DI RELATORE DI ELABORATI DI LAUREA, DI TESI DI LAUREA MAGISTRALE, DI TESI DI DOTTORATO E DI TESI DI SPECIALIZZAZIONE

Relatore Tesi di Dottorato: Rigamonti C (in corso, Università Vita-Salute San Raffaele), Romano A (in corso, Università Vita-Salute San Raffaele), Colantuoni M (2022, Università Vita-Salute San Raffaele), Vacca M (2017, National University of Singapore, Singapore)
Correlatore Tesi di Dottorato: Zoccolillo M (2021, Università di Tor Vergata), Mambwe B (2018, University of Sheffield, UK), Diamond CE (2017, University of Manchester, UK),

Viganò E (2015, Università degli Studi di Milano-Bicocca), Conforti Andreoni C (2011, Università degli Studi di Milano-Bicocca)

Correlatore Tesi Laurea Magistrale: Romano A (2022, Università Vita-Salute San Raffaele), Magnani L (2021, Università Vita-Salute San Raffaele), Milardi G (2019, Università Vita-Salute San Raffaele), Licandro G (2011, Università degli Studi di Milano-Bicocca), Guerrini M (2005, Università degli Studi di Milano), Ferraro A (2004, Università degli Studi di Milano)

Nel periodo compreso tra il 2008 e il 2017, ho supervisionato 5 studenti provenienti da università europee che sono venuti nel mio laboratorio a Singapore per svolgere il loro stage per la tesi magistrale (Evrard M, Thomann SM, Mandriani B, Agragna F, Bonin O)

Correlatore Tesi Laurea Triennale: Ottorini A (2022, Università Vita-Salute San Raffaele), Licandro G (2008, Università degli Studi di Milano-Bicocca), Lazzati S (2007, Università degli Studi di Milano-Bicocca), Marini C (2008, Università degli Studi di Milano-Bicocca), Mastropietro J (2008, Università degli Studi di Milano-Bicocca)

Nel periodo compreso tra il 2008 e il 2017, ho supervisionato 8 studenti provenienti da università europee che sono venuti nel mio laboratorio a Singapore per svolgere il loro stage per la tesi triennale (Tan BK, Alperet DJ, Mili V, Mortellaro E, Zhang'E, Kennedy S, Qi LS, Farrow M)

Esaminatore Tesi Dottorato: Steiner A (2021, University of Melbourne), Giordano MS (2019, Università Vita-Salute San Raffaele), Hruskova Z (2015, Nanyang Technological University, Singapore), Shen Y (2014; National University of Singapore, Singapore), Seow V (2013, The University of Queensland, AU), Harfuddin Z (2013, National University of Singapore, Singapore), Kamran N (2012, National University of Singapore, Singapore)

Esaminatore Tesi Magistrali: Oberrauch F (2019, Università Vita-Salute San Raffaele)

ATTIVITÀ DI RICERCA SCIENTIFICA

PUBBLICAZIONI SCIENTIFICHE

ARTICOLI ORIGINALI

1. Caronni N, La Terza F, Vittoria FM, Barbiera G, Mezzanzanica L, Cuzzola V, Barresi S, Pellegatta M, Canevazzi P, Dunsmore G, Leonardi C, Montaldo E, Lusito E, Dugnani E, Citro A, Ng MSF, Schiavo Lena M, Drago D, Andolfo A, Brugiapaglia S, Scagliotti A, **Mortellaro A**, Corbo V, Liu Z, Mondino A, Dellabona P, Piemonti L, Taveggia C, Doglioni C, Cappello P, Novelli F, Iannacone M, Ng LG, Ginhoux F, Crippa S, Falconi M, Bonini C, Naldini L, Genua M, Ostuni R. IL-1B+ macrophages fuel pathogenic inflammation in pancreatic cancer. *Nature*. 2023;623(7986):415-422. PMID: 37914939.
2. Colantuoni F, Jofra Hernandez R, Pettinato E, Basso-Ricci L, Magnani L, Andolfi G, Rigamonti C, Finardi A, Romeo V, Soldi M, Sergi L, Rocchi M, Scala S, Hoffman HM, Gregori S, Kajaste-Rudnitski A, Sanvito F, Muzio L, Naldini L, Aiuti A, **Mortellaro A**. Constitutive IL-1RA production by modified immune cells protects against IL-1-mediated inflammatory disorders. *Sci Transl Med*. 2023;15(698):eade3856. PMID: 37256935.
3. Barzaghi F, Cicalese MP, Zoccolillo M, Brigida I, Barcella M, Merelli I, Sartirana C, Zanussi M, Calbi V, Bernardo ME, Tucci F, Migliavacca M, Giglio F, Doglio M, Canarutto D, Ferrua F, Consiglieri G, Prunotto G, Saettini F, Bonanomi S, Rovere-Querini P, Di Colo G, Jofra T, Foustieri G, Penco F,

- Gattorno M, Hershfield MS, Bongiovanni L, Ponzoni M, Marktel S, Milani R, Peccatori J, Ciceri F, **Mortellaro A***‡, Aiuti A‡. Case Report: Consistent disease manifestations with a staggered time course in two identical twins affected by adenosine deaminase 2 deficiency. *Front Immunol.* 2022;13:910021. *, corresponding; ‡, senior authors. PMID: 36248833.
4. Zoccolillo M, Brigida I, Barzaghi F, Scala S, Jofra Hernández R, Basso Ricci L, Colantuoni M, Pettinato E, Sergi Sergi L, Milardi G, Capasso A, Lombardo A, Gregori A, Schena F, Cesaro S, Conti F, Pession A, Gattorno M, Lee PY, Naldini L, Cicalese MP, Aiuti A, **Mortellaro A**. Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency. *Blood Advances.* 2021;5(16):3174-3187. PMID: 34424322.
 5. Jofra Hernández R, Calabria A, Sanvito F, De Mattia F, Farinelli G, Scala S, Visigalli I, Carriglio N, De Simone M, Vezzoli M, Cecere F, Migliavacca M, Basso-Ricci L, Omrani M, Benedicenti F, Norata R, Rancoita PMV, Di Serio C, Albertini P, Cristofori P, Naldini L, Gentner B, Montini E, Aiuti A, **Mortellaro A**. Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy. *Mol Ther.* 2020; S1525-0016(20)30487. PMID: 33010230.
 6. Javanmard Khameneh H, Leong KWK, Mencarelli A, Vacca M, Mambwe B, Neo K, Tay A, Zolezzi F, Lee B, **Mortellaro A**. The Inflammasome Adaptor ASC Intrinsically Limits CD4+ T-Cell Proliferation to Help Maintain Intestinal Homeostasis. *Front Immunol.* 2019;10:1566. PMID: 31379813.
 7. Mambwe B, Neo K, Khameneh HJ, Leong KWK, Colantuoni M, Vacca M, Muimo R, **Mortellaro A**. Tyrosine Dephosphorylation of ASC Modulates the Activation of the NLRP3 and AIM2 Inflammasomes. *Front Immunol.* 2019;10:1556. PMID: 31333677.
 8. Pal A, Neo K, Rajamani L, Ferrer FJ, Lane DP, Verma CS, **Mortellaro A**. Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides. *Sci Rep.* 2019; 9(1):4913. PMID: 30894604.
 9. Mencarelli A, Khameneh HJ, Fric J, Vacca M, El Daker S, Janela B, Tang JP, Nabti S, Balachander A, Lim TS, Ginhoux F, Ricciardi-Castagnoli P, **Mortellaro A**. Calcineurin-mediated IL-2 production by CD11chighMHCII+ myeloid cells is crucial for intestinal immune homeostasis. *Nat Commun.* 2018;9(1):1102. PMID: 29549257.
 10. Mencarelli A, Vacca M, Khameneh HJ, Acerbi E, Tay A, Zolezzi F, Poidinger M, **Mortellaro A**. Calcineurin B in CD4+ T Cells Prevents Autoimmune Colitis by Negatively Regulating the JAK/STAT Pathway. *Front Immunol.* 2018;9:261. PMID: 29515579.
 11. Chaurasia SS, Lim RR, Parikh BH, Wey YS, Tun BB, Wong TY, Luu CD, Agrawal R, Ghosh A, **Mortellaro A**, Rackoczy E, Mohan RR, Barathi VA. The NLRP3 Inflammasome May Contribute to Pathologic Neovascularization in the Advanced Stages of Diabetic Retinopathy. *Sci Rep.* 2018;8(1):2847. PMID: 29434227.
 12. Kale SD, Dikshit N, Kumar P, Balamuralidhar V, Khameneh HJ, Bin Abdul Malik N, Koh TH, Tan GGY, Tan TT, **Mortellaro A**, Sukumaran B. Nod2 is required for the early innate immune clearance of *Acinetobacter baumannii* from the lungs. *Sci Rep.* 2017;7(1):17429. PMID: 29234083.
 13. Vacca M, Böhme J, Zambetti LP, Khameneh HJ, Paleja BS, Laudisi F, Ho AWS, Neo K, Leong KWK, Marzuki M, Lee B, Poidinger M, Santambrogio L, Tsenova L, Zolezzi F, De Libero G, Singhal A, **Mortellaro A**. NLRP10 in dendritic cells enhances IFN γ production by antigen-specific T cells. *Front Immunol.* 2017;8:1462. PMID: 29163529.
 14. Diamond CE, Leong KWK, Vacca M, Rivers-Auty J, Brough D, **Mortellaro A**. Salmonella Typhimurium-induced IL-1 release from primary human monocytes requires NLRP3 and occurs in the absence of pyroptosis. *Sci Rep.* 2017;7(1):6861. PMID: 28761045.
 15. Bist P, Cheong WS, Ng A, Dikshit N, Kim BH, Pulloor NK, Khameneh HJ, Hedl M, Shenoy AR, Balamuralidhar V, Malik NBA, Hong M, Neutzner A, Chin KC, Kobayashi KS, Bertolotti A, **Mortellaro A**, Abraham C, MacMicking JD, Xavier RJ, Sukumaran B. E3 Ubiquitin ligase ZNRF4 negatively

- regulates NOD2-signaling and mediates induction of MDP-tolerance. *Nat Commun.* 2017;8:15865. PMID: 28656966.
16. Dikshit N, Kale SD, Khameneh HJ, Balamuralidhar V, Tang CY, Kumar P, Lim TP, Tan TT, Kwa AL, **Mortellaro A**, Sukumaran B. NLRP3 inflammasome pathway plays a critical role in the host immunity against clinically relevant *Acinetobacter baumannii* pulmonary infection. *Mucosal Immunol.* 2017;11(1):257-272. PMID: 28612844.
 17. Khameneh HJ, Ho AW, Laudisi F, Derks H, Kandasamy M, Sivasankar B, Teng GG, **Mortellaro A**. C5a regulates IL-18 production and leukocyte recruitment in a murine model of gout. *Front Pharmacol.* 2017;8:10. PMID: 28167912.
 18. Khameneh HJ, Ho AWS, Spreafico R, Derks H, Quek HQY, Mortellaro A. The Syk-NFAT-IL-2 pathway in dendritic cells is required for optimal sterile immunity elicited by alum adjuvants. *J Immunol.* 2017;198(1):196-204. PMID: 27895176.
 19. Acerbi E, Viganò E, Poidinger M, **Mortellaro A**, Zelante T, Stella F. Continuous time Bayesian networks identify Prdm1 as a negative regulator of TH17 cell differentiation in humans. *Sci Rep.* 2016;6:23128. PMID: 26976045.
 20. Martín-Sánchez F, Diamond C, Zeitler M, Gomez-Sanchez A, Baroja-Mazo A, Bagnall J, Spiller D, White MR, **Mortellaro A**, Peñalver M, Paszek P, Nickel W, Brough D, Pelegrín P. Inflammasome-dependent IL-18 release depends upon membrane permeabilization. *Cell Death Differ.* 2016;23(7):1219-31. PMID: 26868913.
 21. Viganò E, Diamond CE, Spreafico R, Balachander A, Sobota RM, **Mortellaro A**. Human caspase-4 and caspase-5 regulate the one-step non-canonical inflammasome activation in monocytes. *Nat Commun.* 2015;6:8761. PMID: 26508369.
 22. Zelante T, Wong A, Tang JP, Chen J, Sumatoh HRS, Elena Viganò E, Yu HB, Lee B, Zolezzi F, Fric J, Newell EW, **Mortellaro A**, Poidinger M, Puccetti P, Ricciardi-Castagnoli P. CD103⁺ dendritic cells control Th17 cell function in the lung. *Cell Rep.* 2015;12(11):1789-801. PMID: 26365185.
 23. Andiappan AK, Melchiotti R, Poh TY, Nah M, Puan KJ, Viganò E, Haase D, Yusof N, San-Luiz B, Lum J, Kumar D, Foo S, Li L, Vasudev A, Irwanto A, Lee B, Nardin A, Liu H, Zhang F, Connolly J, Liu J, **Mortellaro A**, Wang DY, Poidinger M, Larbi A, Zolezzi F, Rotzschke O. Genome-wide analysis of the genetic regulation of gene expression in human neutrophils. *Nat Commun.* 2015;6:7971. PMID: 26259071.
 24. Li L, Ng DS, Mah W, Almeida FF, Rahmat SA, Rao VK, Leow SC, Laudisi F, Peh MT, Goh AM, Lim JS, Wright GD, **Mortellaro A**, Taneja R, Ginhoux F, Lee CG, Moore PK, Lane DP. A unique role for p53 in the regulation of M2 macrophage polarization. *Cell Death Differ.* 2015;22(7):1081-93. PMID: 25526089.
 25. Zhou Q, Ho AWS, Schlitzer A, Tang Y, Wong KHS, Wong FHS, Chua YL, Angeli V, **Mortellaro A**, Ginhoux F, Kemeny DM. GM-CSF-licensed CD11b⁺ lung DCs orchestrate Th2 immunity to *Blomia tropicalis*. *J Immunol.* 2014;193(2):496-509. PMID: 24943219.
 26. Goh AX, Bertin-Maghit S, Yeo SP, Ho AWS, Derks H, **Mortellaro A**, Wang CI. A novel human anti-interleukin-1b neutralizing monoclonal antibody showing in vivo efficacy. *MAbs.* 2014;6(3):764-72. PMID: 24671001.
 27. Bist P, Dikshit N, Koh TH, **Mortellaro A**, Tan TT, Sukumaran B. The Nod1, Nod2, and Rip2 axis contributes to host immune defense against intracellular *Acinetobacter baumannii* infection. *Infect Immun.* 2014;82(3):1112-22. PMID: 24366254.
 28. Laudisi F, Spreafico R, Evrard M, Hughes TR, Mandriani B, Kandasamy M, Morgan BP, Sivasankar B, **Mortellaro A**. Cutting edge: The NLRP3 inflammasome links complement-mediated inflammation and IL-1b release. *J Immunol.* 2013;191(3):1006-10. [Reviewed in F1000Prime, f1000.com/prime/718046840]. PMID: 23817414.

29. Licandro G, Khor HL, Beretta O, Lai J, Derks H, Laudisi F, Conforti-Andreoni C, Qian HL, Teng GG, Ricciardi-Castagnoli P, **Mortellaro A**. The NLRP3 inflammasome affects DNA damage responses after oxidative and genotoxic stress in dendritic cells. *Eur J Immunol*. 2013;43(8):2126-37. [Selected for cover image and Editorial Commentary]. PMID: 23619996.
30. Lim TS, Goh JK, **Mortellaro A**, Lim CT, Hämmerling GJ, Ricciardi-Castagnoli P. CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells. *PLoS One*. 2012;7(9):e45185. PMID: 23024807.
31. Fric J, Lim CFX, Koh EGL, Hofmann B, Chen J, Tay HS, Isa SA, **Mortellaro A**, Ruedl C, Ricciardi-Castagnoli P. Calcineurin/NFAT signaling inhibits myeloid hematopoiesis. *EMBO Mol Med*. 2012;4(4):269-85. PMID: 22311511.
32. Lin M., Isa SA, Wee NF, Siu KS, Beretta O, **Mortellaro A**, Ruedl C. Synergism between curdlan and GM-CSF confers a strong inflammatory signature to dendritic cells. *J Immunol*. 2012;188(4):1789-98. PMID: 22250091.
33. Conforti-Andreoni C, Spreafico R, Qian HL, Riteau N, Ryffel B, Ricciardi-Castagnoli P, **Mortellaro A**. Uric acid-driven Th17 differentiation requires inflammasome-derived IL-1 and IL-18. *J Immunol*. 2011;187(11):5842-50. PMID: 22058415.
34. Lim TS, **Mortellaro A**, Lim CT, Hämmerling GJ, Ricciardi-Castagnoli P. Mechanical interactions between dendritic cells and T cells correlate with T cell responsiveness. *J Immunol*. 2011;187(1):258-65. PMID: 21622857.
35. Conforti-Andreoni C, Beretta O, Licandro G, Qian HL, Urbano M, Vitulli F, Ricciardi-Castagnoli P, **Mortellaro A**. Synergism of NOD2 and NLRP3 activators promotes a unique transcriptional profile in murine dendritic cells. *J Leukoc Biol*. 2010; 88(6):1207-1216. PMID: 20884650.
36. Tailleux L, Waddell SJ, Pelizzola M, **Mortellaro A***, Withers M, Tanne A, Castagnoli PR, Gicquel B, Stoker NG, Butcher PD, Foti M, Neyrolles O. Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. *PLoS One*. 2008;3(1):e1403. (*First co-authorship). PMID: 18167562.
37. **Mortellaro A**, Hernandez RJ, Guerrini MM, Carlucci F, Tabucchi A, Ponzoni M, Sanvito F, Doglioni C, Di Serio C, Biasco L, Follenzi A, Naldini L, Bordignon C, Roncarolo MG, Aiuti A. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. *Blood*. 2006;108(9):2979-88. PMID: 16835374.
38. Guazzi V, Aiuti F, Mezzaroma I, Mazzetta F, Andolfi G, **Mortellaro A**, Pierdominici M, Fantini R, Marziali M, Aiuti A. Assessment of thymic output in common variable immunodeficiency patients by evaluation of T cell receptor excision circles. *Clin Exp Immunol*. 2002;129(2):346-53. PMID: 12165093.
39. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, **Mortellaro A**, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. *Science*. 2002;296(5577):2410-3. PMID: 12089448.
40. Aiuti A, Vai S, **Mortellaro A**, Casorati G, Ficara F, Andolfi G, Ferrari G, Tabucchi A, Carlucci F, Ochs HD, Notarangelo LD, Roncarolo MG, Bordignon C. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. *Nat Med*. 2002;8(5):423-5. PMID: 11984564.
41. **Mortellaro A**, Songia S, Gnocchi P, Ferrari M, Fornasiero C, D'Alessio R, Isetta A, Colotta F, Golay J. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation. *J Immunol*. 1999;162(12):7102-9. PMID: 10358154.
42. Songia S, **Mortellaro A**, Taverna S, Fornasiero C, Scheiber EA, Erba E, Colotta F, Mantovani A, Isetta AM, Golay J. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. *J Immunol*. 1997;158(8):3987-95. PMID: 9103470.

REVIEWS, EDITORIALS, COMMENTARIES AND BOOK CHAPTERS

43. Bulté D, Rigamonti C, Romano A, **Mortellaro A**. Inflammasomes: Mechanisms of Action and Involvement in Human Diseases. *Cells*. 2023;12(13):1766. PMID: 37443800.
44. **Mortellaro A**. Editorial: NLRP3 Activation and Regulation in Innate Immune Responses. *Front Immunol*. 2023;14:1171138.
45. Magnani L, Colantuoni M, **Mortellaro A**. Gasdermins: New Therapeutic Targets in Host Defense, Inflammatory Diseases, and Cancer. *Front Immunol*. 2022;13:898298. PMID: 35844522.
46. Mesa-Núñez C, **Mortellaro A**. T cells and monocytes: A dangerous liaison in adenosine deaminase 2 deficiency. *J Leukoc Biol*. 2022;111(2):297-299. PMID: 35090065
47. Tucci F, Scaramuzza S, Aiuti A, **Mortellaro A**. Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases. *Mol Ther*. 2021;29(2):489-504. PMID: 33221437.
48. Diamond C, Bagnall J, Spiller DG, White MR, **Mortellaro A**, Paszek P, Brough D. Investigating IL-1B Secretion Using Real-Time Single-Cell Imaging. *Methods Mol Biol*. 2016;1417:75-88. PMID: 27221482.
49. Diamond CE, Khameneh HJ, **Mortellaro A**. Novel perspectives on non-canonical inflammasome activation. *ImmunoTargets and Therapy*. 2015;4:131. PMID: 27471719.
50. Khameneh HJ, **Mortellaro A**. NLRC4 gets out of control. *Nat Genet*. 2014;46(10):1048. PMID: 25257084.
51. Zambetti LP, **Mortellaro A**. NLRPs, microbiota and gut homeostasis: unraveling the connection. *J Pathol*. 2014;233(4):321. PMID: 24740681.
52. Laudisi F, Viganò E, **Mortellaro A**. Tyrosine kinases: the molecular switch for inflammasome activation. *Cell Mol Immunol*. 2014;11(2):129. PMID: 24509443.
53. Viganò E, **Mortellaro A**. Caspase-11: the driving factor for non-canonical inflammasomes. *Eur J Immunol*. 2013;43(9):2240. PMID: 24037676.
54. Zambetti LP, Laudisi F, Licandro G, Ricciardi-Castagnoli P, **Mortellaro A**. The rhapsody of NLRPs: master players of inflammation ... and a lot more. *Immunol Res*. 2012;53(1-3):78. PMID: 22427013.
55. **Mortellaro A**, Ricciardi-Castagnoli P. From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease. *Immunol Cell Biol*. 2011;89(3):332. PMID: 21301476.
56. Conforti-Andreoni C, Ricciardi-Castagnoli P, **Mortellaro A**. The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. *Cell Mol Immunol*. 2011;8(2):135. PMID: 21258359.
57. Spreafico R, Ricciardi-Castagnoli P, **Mortellaro A**. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. *Eur J Immunol*. 2010;40(3):638. PMID: 20201020.
58. **Mortellaro A**, Wong SC, Fric J, Ricciardi-Castagnoli P. The need to identify myeloid dendritic cell progenitors in human blood. *Trends Immunol*. 2010;31(1):18. PMID: 19836307.
59. **Mortellaro A**, Robinson L, Ricciardi-Castagnoli P. Spotlight on Mycobacteria and dendritic cells: will novel targets to fight tuberculosis emerge? *EMBO Mol Med*. 2009;1(1):19. PMID: 20049700.
60. **Mortellaro A**, Urbano M, Citterio S, Foti M, Granucci F, Ricciardi-Castagnoli P. Generation of murine growth factor-dependent long-term dendritic cell lines to investigate host-parasite interactions. *Methods Mol Biol*. 2009;531:17. PMID: 19347308.

61. **Mortellaro A**, Granucci F, Foti M, Ricciardi-Castagnoli P. Dendritic cells in their tissue microenvironments during exposure to pathogens. Editors: David G. Russell and Siamon Gordon, 2009;51-68. ASM Press. PMID: 18672083.
62. **Mortellaro A**, Conforti-Andreoni C, Fric J, Ricciardi-Castagnoli P. Dendritic cells as sensors of environmental perturbations. **Microbes Infect.** 2008;10(9):990.2.

FINANZIAMENTI

2023-2024	Collaboratore Principale, PNRR M6/C2_Call 2022, €1,000,000 totale Definition of a personalized signature of chronic inflammation and early aging predictive of the development of comorbidities in infertile men
2022-2024	Investigatore Principale, Telethon Core Grant, €540,000 totale Understanding the pathogenesis and developing better therapies for adenosine deaminase 2 deficiency
2021-2024	Collaboratore Principale, Ministero della Salute, Bando della Ricerca Finalizzata 2019, €540,000 totale Expanding the spectrum of adenosine deaminase 2 (ADA2) deficiency: towards a gene therapy approach
2019-2021	Investigatore Principale, Telethon Core Grant, €90,000 totale Study of the pathogenesis and development of gene therapy for adenosine deaminase 2 deficiency
2019-2021	Destinatario, Marie Skłodowska-Curie Actions, Individual Fellowship, European Commission, €183,473 totale Development of gene therapy and genome editing strategies to treat adenosine deaminase 2 deficiency
2019-2021	Co-Investigatore, Jeffrey Modell Foundation, Translational Research Program, \$200,000 totale Preclinical development of a hematopoietic stem cell gene therapy for adenosine deaminase 2 deficiency
2011-2017	Investigatore Principale, SgN/A*STAR Core Funds, S\$700,000 per anno per 6 anni Questi fondi hanno coperto i salari dell'Investigatore Principale e di 4 membri dello staff (2 postdoc e 2 assistenti di ricerca), così come i costi operativi e quelli indiretti
2016-2017	Investigatore Principale, A*STAR-NTU-NHG 2nd Skin Research Grant, S\$225,000 totale Targeting the inflammasome pathway for therapeutic treatment of atopic dermatitis
2014-2015	Investigatore Principale, YRCG JCO/A*STAR Grant, S\$198,200 totale The Role of Electrostatic Charge in Particulate-Mediated Activation of the NLRP3 Inflammasome
2014-2015	Co-Investigatore, NMRC Grant, S\$199,240 totale Role of NLRP3 Inflammasome Activation in the Pathogenesis of Gout and Correlation with Disease Severity
2014	Study Director, JCO/A*STAR Grant 2014, 11th call, S\$192,000 totale Suppressing NLRP3 inflammasome activity in immune cells by high affinity stapled/dual peptides

PARTECIPAZIONE A COMITATI EDITORIALI DI RIVISTE SCIENTIFICHE

2010-2023: Editore Associato di Frontiers in Immunology

2010-2023: Membro del Board Editoriale di Scientific Reports, Immunology session

ATTIVITÀ DI REVISIONE DI GRANT

Swiss National Science Foundation (SNF), French National Research Agency (ANR), Israel Science Foundation (ISF), Singapore National Medical Research Council (NMRC), DBT/Wellcome Trust India Alliance, Hong Kong Research Grant Council (HKRGC)

TITOLARITÀ DI BREVETTI

2023 IL-1RA Gene therapy. File #EP23164177

2017 Stapled peptides for suppression of the NLRP3 Inflammasome activation. File#10201702246Q

2013 IL-18 neutralizing human monoclonal antibodies. File #PCT/SG2013/000057. Licenziato.

PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA

2011 Destinataria del Premio Giovane Investigatore ottenuto dalla Lega delle Associazioni di Reumatologia

2019 Destinataria della Borsa di Studio Individuale Marie Skłodowska-Curie finanziata nell'ambito del programma Horizon 2020 dalla Commissione Europea

ATTIVITÀ GESTIONALI, ORGANIZZATIVE E DI SERVIZIO

Da Gennaio 2023, ricopro la posizione di referente dipartimentale per la Medicina di Genere, un necessario strumento di eccellenza scientifica come previsto dalle indicazioni della Commissione Europea

Data

19/12/2023

Luogo

Milano